Research suggests that integrin signaling plays a role in cancer resistance and progression. Integrin α6/Akt/Erk signaling is specifically implicated in human breast cancer resistance to radiotherapy. The involvement of integrins in various types of cancer, including prostate, gastrointestinal, and hepatocellular carcinoma, is also being studied, with potential implications for targeted therapies.